NeuroMetrix (NASDAQ:NURO) Now Covered by Analysts at StockNews.com

Analysts at StockNews.com began coverage on shares of NeuroMetrix (NASDAQ:NURO) in a research note issued on Monday. The firm set a “sell” rating on the medical device company’s stock.

NeuroMetrix Trading Up 0.5 %

Shares of NURO opened at $3.94 on Monday. NeuroMetrix has a 12 month low of $2.66 and a 12 month high of $4.73. The stock has a fifty day moving average price of $4.01 and a 200-day moving average price of $3.85. The firm has a market cap of $8.05 million, a PE ratio of -0.86 and a beta of 2.18.

NeuroMetrix (NASDAQ:NURO) last issued its quarterly earnings results on Tuesday, November 5th. The medical device company reported ($0.75) earnings per share (EPS) for the quarter. The company had revenue of $0.59 million for the quarter. NeuroMetrix had a negative net margin of 203.71% and a negative return on equity of 42.56%. During the same quarter last year, the firm earned ($1.66) EPS.

About NeuroMetrix

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.